FILANA THERAPEUTICS INC
FLNANASDAQ🏆 #4494 by market capUS Equity
$0.93▲ $0.08 (+8.77%)
Market closed · at closeTrack FLNA
Get earnings, price moves & breaking news on Telegram
24h▲ 8.8%
7d▲ 5.6%
14d▲ 36.6%
30d▲ 5.2%
ytd▼ 52.7%
1y▼ 67.8%
🏦Market Cap
$45M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
17.8%
Healthy
⚖️P/S Ratio
1.1x
Cheap
Otter Score
96
Very Good
Trading Snapshot
- Day Range
- $0.92 – $0.94
- 52-Week Range
- $0.67 – $2.27
- Volume
- $2.56B
- Avg Volume
- $2.81B
- Shares Outstanding
- 48.3M
- Next Earnings
- Nov 23, 2026
Fundamentals Snapshot
- Annual Revenue
- $41M
- Last Q Revenue
- $10M
- P/E Ratio
- —
- P/S Ratio
- 1.1x
- EPS (TTM)
- $-0.88
- Dividend Yield
- —
- Dilution (1yr)
- −99.0%
Why Investors Own FLNA
- ✓High-growth profile — revenue up +39.5% YoY with expanding US Equity exposure.
- ✓Healthy economics — 62% gross margin and 5% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
FILANA THERAPEUTICS INC
FLNAFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$95M▼ −32.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
48.3M▼ −99.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$96M▼ −$33M YoY
StockOtter · stockotter.spaceAbout FILANA THERAPEUTICS INC
Filana Therapeutics, Inc. is a company dedicated to pioneering new pharmaceutical products and diagnostic technologies. A key area of its research is focused on creating potential treatments for Alzheimer's disease, including the investigational compounds PTI-125 and PTI-125Dx. Established by Remi Barbier in May 1998, the firm maintains its principal office in Austin, Texas.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Very Good
96/100
Analyst Price Target
ⓘAverage Target
$0.98
▲ +5.1% Upside
High Target$1.21
Low Target$0.84
Based on 24 analysts
Latest News & Updates
🚀
Reuters·2h ago
FILANA THERAPEUTICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
CNBC·5h ago
Analysts lift FLNA price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Reuters·1d ago
FILANA THERAPEUTICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.